Annovis Bio, Inc.
NYSE:ANVS
4.37 (USD) • At close December 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Annovis Bio, Inc. |
Symbool | ANVS |
Munteenheid | USD |
Prijs | 4.37 |
Beurswaarde | 60,293,764 |
Dividendpercentage | 0% |
52-weken bereik | 4.31 - 22.49 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Maria L. Maccecchini Ph.D. |
Website | https://www.annovisbio.com |
An error occurred while fetching data.
Over Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)